Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (57,277)	$ (52,953)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	3,287	4,301
Depreciation and amortization	1,767	1,014
Non-cash interest expense	206	229
Other	11	(1,549)
Intangible impairment charge		23,200
Change in fair value of contingent consideration liability	1,316	(5,900)
Changes in assets and liabilities:
Accounts receivable	(2,374)	(1,813)
Other current assets	(2,350)	(1)
Other assets	(2,382)
Accounts payable	240	(2,714)
Accrued expenses	1,994	(1,874)
Other current liabilities	60
Other liabilities	(369)	218
Net cash used in operating activities	(55,871)	(37,842)
Cash flows from investing activities:
Acquisition of AZEDRA manufacturing assets	(8,000)
Purchases of property and equipment	(4,465)	(595)
Portion of MIP milestones paid to former advisor	(277)
Net cash used in investing activities	(12,742)	(595)
Cash flows from financing activities:
Repayment of debt	(3,880)	(3,368)
Proceeds from exercise of stock options	1,313	467
Net cash (used in) provided by financing activities	(2,567)	96,739
Effect of currency rate changes on cash, cash equivalents and restricted cash	(220)	(86)
Net decrease in cash, cash equivalents, and restricted cash	(71,400)	58,216
Cash, cash equivalents, and restricted cash at beginning of period	139,220	92,164
Cash, cash equivalents, and restricted cash at end of period	67,820	150,380
Supplemental disclosure of cash flow information
Cash paid for interest	3,146	3,535
Cash, cash equivalents and restricted cash information
Cash and cash equivalents at beginning of period	137,686	90,642
Restricted cash included in long-term assets at the beginning of period	1,534	1,522
Cash, cash equivalents, and restricted cash at beginning of period	139,220	92,164
Cash and cash equivalents at end of period	64,493	148,851
Restricted cash included in long-term assets at the end of period	3,327	1,529
Cash, cash equivalents, and restricted cash at end of period	67,820	150,380
Public Offering [Member]
Cash flows from financing activities:
Net proceeds common stock		69,987
At-the-market Offering [Member]
Cash flows from financing activities:
Net proceeds common stock		$ 29,653